Jazz Tunes Up For Business Development
This article was originally published in The Pink Sheet Daily
Executive Summary
With a highly competitive effective tax rate, half a billion dollars in cash, and access to attractively priced capital, specialty pharma Jazz, itself the subject of takeover rumors, has stepped up its ongoing hunt for late-stage assets.